Revenue: As of FY2025 Q2, the actual value is USD 119.8 M.EPS: As of FY2025 Q2, the actual value is USD -0.15.EBIT: As of FY2025 Q2, the actual value is USD -11.21 M.<h3>Segment Revenue</h3><ul><li>Consolidated Revenue: $119.8 million, an increase of 21.5% from $98.6 million in Q2 2024.</li><li>Patient Services Revenue: $55.9 million, up from $52.5 million.</li><li>Dispensary Revenue: $62.6 million, up from $44.4 million.</li><li>Clinical Trials &amp; Other Revenue: $1.3 million, down from $1.7 million.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: $17.5 million, an increase of 34.4%.</li><li>Net Loss: - $17.0 million, compared to - $15.5 million in Q2 2024.</li><li>Adjusted EBITDA: - $4.1 million, compared to - $8.7 million.</li></ul><h3>Cash Flow</h3><ul><li>Cash and Cash Equivalents: $30.3 million as of June 30, 2025.</li><li>Net Cash Used in Operating Activities: - $15.2 million for the six months ended June 30, 2025, compared to - $31.5 million in 2024.</li><li>Free Cash Flow: - $14.6 million, compared to - $31.8 million in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Fee-for-Service Revenue Growth: 10% over Q2 2024, driven by new markets.</li><li>Retail Pharmacy and Dispensary Contribution: $62.6 million in revenue and over $11 million in gross profit in Q2 2025.</li></ul><h3>Outlook / Guidance</h3><ul><li>The Oncology Institute reaffirms its full-year 2025 guidance with expected revenue between $460 to $480 million and gross profit between $73 to $82 million.</li><li>Adjusted EBITDA is projected to be between - $8 to - $17 million, and Free Cash Flow is expected to be between - $12 to - $21 million.</li><li>The company anticipates reaching the higher end of its revenue guidance range for 2025, with Adjusted EBITDA expected to be approximately - $2.5 to - $3.5 million in Q3 2025.</li></ul>

Oncology Institute - CW22 | 8-K: FY2025 Q2 Revenue: USD 119.8 M